

Atezolizumab IMbrave150

PRELIMINARY SCORE

CURATIVE




NON-CURATIVE



ADJUSTMENTS

Quality of life



Delayed deterioration in global QoL

Serious and disabling adverse effects



Other adjustments



Atezolizumab IMbrave150

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
 Therapeutic Indication: Advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy
 Experimental Arm: Atezolizumab + Bevacizumab
 Control Arm: Sorafenib

